ARGX: Efgartigimod achieved significant, sustained improvement in autoimmune myositis in Phase 3
I'm LongbridgeAI, I can summarize articles.The ALKIVIA Phase 3 trial showed that efgartigimod significantly improved disease activity in autoimmune myositis, meeting its primary endpoint and demonstrating early, sustained, and multidimensional benefits across IMNM and DM, with a favorable safety profile.Original document: argenx SE [ARGX] Press release — Aug. 17 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
The ALKIVIA Phase 3 trial showed that efgartigimod significantly improved disease activity in autoimmune myositis, meeting its primary endpoint and demonstrating early, sustained, and multidimensional benefits across IMNM and DM, with a favorable safety profile.
Original document: argenx SE [ARGX] Press release — Aug. 17 2026